These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 30595323

  • 1. Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naïve dyslipidemic patients.
    Kumar M, Rehan HS, Puri R, Yadav M, Gupta LK.
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S64-S67. PubMed ID: 30595323
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.
    Pareek A, Chandurkar N, Thulaseedharan NK, Legha R, Agarwal M, Mathur SL, Salkar HR, Pednekar S, Pai V, Sriram U, Khyalappa R, Parmar M, Agrawal N, Dhruv U, Saxena S.
    Curr Med Res Opin; 2015 Nov; 31(11):2105-17. PubMed ID: 26371518
    [Abstract] [Full Text] [Related]

  • 3. Correlation of compliance to statin therapy with lipid profile and serum HMGCoA reductase levels in dyslipidemic patients.
    Grover A, Rehan HS, Gupta LK, Yadav M.
    Indian Heart J; 2017 Nov; 69(1):6-10. PubMed ID: 28228309
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK.
    Circulation; 2018 Aug 21; 138(8):770-781. PubMed ID: 29618599
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 21; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
    Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M.
    J Cardiovasc Pharmacol Ther; 2003 Jun 21; 8(2):123-6. PubMed ID: 12808485
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
    Pattanaik S, Malhotra S, Sharma YP, Pandhi P.
    J Cardiovasc Pharmacol; 2012 May 21; 59(5):479-84. PubMed ID: 22569288
    [Abstract] [Full Text] [Related]

  • 11. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 21; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 12. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC, Davidson MH, Kelly MT, Setze CM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):117-25. PubMed ID: 22263674
    [Abstract] [Full Text] [Related]

  • 13. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK.
    DNA Cell Biol; 2010 Oct 01; 29(10):629-37. PubMed ID: 20578904
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects.
    Mladenovska K, Grapci AD, Vavlukis M, Kapedanovska A, Eftimov A, Geshkovska NM, Nebija D, Dimovski AJ.
    Pharmazie; 2017 May 01; 72(5):288-295. PubMed ID: 29441875
    [Abstract] [Full Text] [Related]

  • 17. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov 01; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effects of atorvastatin on interventional therapy in patients with acute myocardial infarction.
    Wang K, Chen L, Liu L, Cui Y, Zhang X, Jiang J.
    Minerva Med; 2019 Apr 01; 110(2):101-106. PubMed ID: 29696937
    [Abstract] [Full Text] [Related]

  • 20. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW.
    Am J Cardiovasc Drugs; 2005 Apr 01; 5(6):379-87. PubMed ID: 16259526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.